News for Exelixis, Inc. (EXEL)

PR NewswireVANCOUVER, BC, March 8, 2025 USA News Group News CommentaryIssued on behalf of Oncolytics Biotech Inc.VANCOUVER, BC, March 8, 2025 /PRNewswire/

NEW YORK, March 03, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. ( OVID), a biopharmaceutical company dedicated to developing small-molecule medicines for

Gilead Sciences, Exelixis, Synchrony Financial and Molson Coors have been highlighted in this Screen of The Week article.

Exelixis Inc (EXEL), a leading oncology company, has announced its participation in several significant investor conferences in March. The company will engage i

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiat...

We recently published a list of Renaissance Technologies Portfolio: Top 10 Stock Picks. In this article, we are going to take a look at where Exelixis, Inc.

The American quant hedge fund Renaissance Technologies is known for using statistical and mathematical tools to drive its investment programs.

Exelixis Inc (EXEL) has announced that its Board of Directors has approved an additional $500 million stock repurchase program, set to be completed by December

Exelixis Inc (EXEL), a prominent biopharmaceutical company known for its cancer treatments, experienced a notable 5.02% increase in its stock price. This positi

Exelixis (EXEL) announces a $500M stock repurchase program through 2025. Learn about their strategy and potential impact on investors.

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both.

Exelixis (EXEL) could produce exceptional returns because of its solid growth attributes.

Industry veteran CFO Frank Karbe brings more than 25 years of leadership experience in the biopharma industry transitioning companies from R&D to commercializa

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Revenue: $567 million for Q4 2024, surpassing the estimated $563.42 million.Earnings Per Share (EPS): GAAP diluted EPS of $0.48 for Q4 2024, exceeding the esti

On December 31, 2024, Caligan Partners LP (Trades, Portfolio) made a strategic move by acquiring 15,856,653 shares of Verrica Pharmaceuticals Inc. This transact

Exelixis reported $515.2M in net product revenues in Q4'24, a 20% increase over net product revenues for Q4'23. See why I rate EXEL stock a buy.

Total Revenue: Approximately $567 million for Q4 2024.Cabozantinib Franchise Net Product Revenue: $515.2 million for Q4 2024.CABOMETYX Net Product Revenue: $51

Earnings Call Insights: Exelixis, Inc. (NASDAQ:EXEL) Q4 2024Management ViewCEO Mike Morrissey highlighted significant momentum in 2024, emphasizing the...